Background {#Sec1}
==========

Assisted reproductive technologies (ART) are used to treat infertility problems and contain methods in which oocyte and sperm are manipulated in vitro \[[@CR1]\]. The use of ART has increased exponentially worldwide and is responsible for over than one million births annually \[[@CR2], [@CR3]\]. Having been treated by ART, the women who conceived had numerous adverse outcomes, both for themselves and the infants \[[@CR3]\]. Previous studies have demonstrated that ART is associated with small for gestational age infants, preterm delivery, perinatal mortality, preeclampsia (PE), gestational diabetes, placenta previa, placental abruption, and cesarean delivery \[[@CR4]\]. Of several adverse pregnancy consequences, hypertensive disorders affect 6--8% of all pregnancies through gestational hypertension and PE \[[@CR5], [@CR6]\]. In contrast to spontaneous pregnancy, pregnancies with ART are at an increased risk of PE \[[@CR7]\]. It remained unclear whether either ART itself \[in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), oocyte donation (OD), or embryo donation (ED)\] or maternal risk factors associated with ART (that is, advanced maternal age, obesity, change of partner, longer interval between births, reduced smoking, and chronic hypertension) were related to increased risk of PE \[[@CR7], [@CR8]\]. Some studies have shown the probability of the taking of some medications during pregnancy, such as low-dose aspirin, \[[@CR9]\] prevents for PE in high-risk women \[[@CR10]--[@CR12]\]. Thus, identifying high-risk women during the early period of gestation will be worthwhile for the prevention and management of the pregnancy complications \[[@CR13]\]. Finally, the lack of diagnostic criteria for pregnancy complications associated with hypertension, especially for PE, make the research in this field more complicated \[[@CR14]\].

In the present paper, the authors conducted a comprehensive systematic review of ART procedures and PE. The aim of this review was to investigate whether ART mediated pregnancies (i.e., IUI, IVF, ICSI, OD, and ED) increased the incidence of PE in pregnancy compared with spontaneous pregnancies.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

This meta-analysis was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist \[[@CR15]\]. We conducted a systematic literature search in Medline/PubMed, Embase, Scopus, and the ISI Web of Knowledge from inception through June 2017 for studies examining the association between ART and PE. In addition, reference lists from all retrieved papers were checked. Table [1](#Tab1){ref-type="table"} provides more details about the search strategy.Table 1Search strategy for MEDLINE (MeSH, Medical Subject Headings)1Preeclampsia \[Text Word\])2Pre-Eclampsia \[Text Word\])3"Pre-Eclampsia" \[Text Word\])4"Pre-Eclampsia" \[MeSH Terms\]51 OR 2 OR 3 OR 46Reproductive Techniques, Assisted \[Text Word\]7Reproductive Techniques, Assisted \[MeSH Terms\]86 OR 79Cohort Studies \[Text Word\]10Cohort Studies \[MeSH Terms\]11Retrospective Studies \[Text Word\]12Retrospective Studies \[MeSH Terms\]13Prospective Studies \[Text Word\]14Prospective Studies \[MeSH Terms\]15Case-Control Studies \[Text Word\]16Case-Control Studies \[MeSH Terms\]179 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16185 AND 8 AND 17

Inclusion and exclusion criteria {#Sec4}
--------------------------------

We included published case-control studies and cohort studies evaluating the association between ART and PE risk. No geographic restrictions were used. The following types of studies were excluded: (a) non-English full-text studies, (b) animal studies, (c) repeated or overlapping studies, (d) reviews, meta-analysis and cross-sectional articles, case reports, editorials, and letters to the editor, (e) abstract-only publications or unpublished studies. There were five case-control studies added to the study. However, it was not substantially possible to estimate the relative risk (RR) with case-control design due to the fact that the marginal probabilities were not available; under the rare disease assumption, the odds ratio will be approximate the RR.

Outcome and exposure {#Sec5}
--------------------

In the present study, all types of ART treatments were considered as the interested exposure variable. Our outcome was PE defined as "elevated blood pressure (BP) (more than 140/100 mmHg) and proteinuria (0.3 g over 24 hours or more)."

Data extraction {#Sec6}
---------------

Two authors (MM and SM) independently extracted the following data from all studies meeting the inclusion criteria: first author's name, year of publication, location, study period, design, sample size, and study results. In addition, outcome data were extracted from each study in a 2 × 2 table, and the results were expressed as RR with their respective 95% confidence intervals (CIs) \[[@CR9]\].

Quality assessment {#Sec7}
------------------

Two authors (MM and SM) independently assessed the quality of studies using the Newcastle--Ottawa Scale (NOS) \[[@CR16]\]. This scale assesses methodology in three domains: (a) selection of study groups, (b) comparability of groups, and (c) ascertainment of exposure and outcomes. Total score ranged from 0 to 9 with a score of ≥8 indicating high quality.

Statistical analysis {#Sec8}
--------------------

Statistical analysis was conducted using Stata version 13.0 (Stata Corp, College Station, TX, USA). The RR was used as the effect size of association across studies. The Cochran Q test and the I^2^ statistic were used to evaluate heterogeneity among studies \[[@CR17]\]. Concerning the Cochrane Q test, *P* \< 0.10 was deemed statistically significant for heterogeneity. The I^2^ statistic indicates the percentage of total variation across studies that is due to heterogeneity rather than chance and is classified as mild (25%), moderate (50%), or high (75%) \[[@CR17]\]. The Galbraith plot was used to detect the potential sources of heterogeneity \[[@CR18]\]. The pooled RR estimate and corresponding 95% CI were calculated by using the random-effect model incorporating between-study variability. The Begg's rank correlation test, Egger's weighted regression test, and visual inspection of a funnel plot were used to assess publication bias \[[@CR19], [@CR20]\]. All tests were two-tailed and a *P* value of \< 0.05 was deemed statistically significant.

Results {#Sec9}
=======

Study selection {#Sec10}
---------------

The process of study selection is illustrated in Fig. [1](#Fig1){ref-type="fig"}. A total of 1244 relevant papers were identified using diverse search strategies in four databases (113 from PubMed, 140 from Embase, 897 from Scopus, and 94 from Web of Knowledge) and three records of gray literature. After removing duplicates, 1057 papers remained, and 749 papers were deemed ineligible after title and abstract screening, and 308 relevant papers were considered for further screening through full-text reading. After the exclusion of all non-eligible studies (*n* = 260), a total of 48 studies (5 case-control studies and 43 cohort studies) were included in this meta-analysis.Fig. 1Flow diagram of study process

Study characteristics {#Sec11}
---------------------

For each study, sample size, total number of ART and non-ART group, number of PE cases in each group, publication date, first author, target country, type of study, and participant mean age of each group were extracted. Cross-sectional studies and non-English studies were excluded from the meta-analysis. All of the primary studies were published between 1999 and 2017 and out of 48 studies, 11 were carried out in the United States, 11 in Asia, and 26 in Europe. The characteristics of studies considered in the meta-analysis are presented in Table [2](#Tab2){ref-type="table"}.Table 2Characteristics of the primary studies included in the meta-analysisAuthorDOPCountryPeriodDesignPE in ARTART groupPE in NARTNART groupJulie Hoy \[[@CR42]\]1999Australia1982--1995Cohort13115523997717O.Salha \[[@CR43]\]1999UK1992--1997Cohort131121112A.Geipel \[[@CR44]\]2001Germany1995--1999Cohort611411114Anne Lynch \[[@CR45]\]2002USA1994--2000Cohort2719840330Syeda Zaib-un-Nisa \[[@CR46]\]2003Emirates1997--2001Cohort436496Pinborg \[[@CR47]\]2004Denmark1997Cohort7187049566Barbara Luke \[[@CR48]\]2004USA1990--2002Cohort2522824725Bengt Kallen \[[@CR49]\]2005Sweden1982--2001Cohort97813,26155,7282,013,633Fiona Thomson \[[@CR50]\]2005Scotland1989--1999Cohort70143755621,688Sonia Hernandez-Diaz \[[@CR51]\]2006USA & Canada1998--2006Cohort183491154762Erez \[[@CR52]\]2006Israel1988--2002Cohort512921932336Prefumo \[[@CR53]\]2007UKNACase Control131162Apantaku \[[@CR24]\]2008UK1999--2004Cohort688788Chen \[[@CR54]\]2009Canada2005Cohort341357775190Sun \[[@CR55]\]2009Canada2004--2007Cohort3121181128420Morcel \[[@CR56]\]2010France2001--2005Cohort1210413173Miyake \[[@CR57]\]2010Japan2005--2007Cohort1520111230Suzuki \[[@CR58]\]2010Japan2000--2007Cohort464987Lehnen \[[@CR28]\]2011Germany2000--2009Cohort10748305Yang \[[@CR59]\]2011Korea1995--2008Cohort96722143Kuivasaari-Pirinen \[[@CR60]\]2012Finland1996--2007Cohort1625596726,870Bamberg \[[@CR61]\]2012Germany1998--2008Cohort1442624813Lubovnik \[[@CR62]\]2012Slovenia1997--2009Case Control55246126477Sazonova \[[@CR63]\]2012Sweden2002--2006Cohort52011,29215,984571,914Mohammed \[[@CR64]\]2012Qatar2002--2011Cohort2714530175Le Ray \[[@CR65]\]2012France2008--2010Cohort241449236Emily Werder \[[@CR66]\]2013USA2002--2008Cohort4521562232Sara S. Malchau \[[@CR67]\]2013Denmark1995--2010Cohort118524,305251956,022Rocio Revello \[[@CR68]\]2013Italy2000--1010Cohort28881459Sari Raisanen \[[@CR69]\]2013Finland2006--2010Cohort9056473138285,357Alex Fong \[[@CR70]\]2014USA2009Case Control295517487406,334Nathan S. Fox \[[@CR71]\]2014USA2005--2012Case Control6137615137Tandberg \[[@CR39]\]2014Norway1967--2009Cohort5516854924,971493,217Tali Silberstein \[[@CR72]\]2014IsraelNACohort11312947889171,513Cagrı Arıoglu Aydın \[[@CR23]\]2015Istanbul2007--2010Cohort1313746133Anne-Maude Morency \[[@CR73]\]2015Canada2000--2013Cohort39181449Robert Johnston \[[@CR27]\]2015USA2009Cohort295517847406,334Malinda S. Lee \[[@CR74]\]2015USA2006--2008Cohort171081762284Bay \[[@CR75]\]2016Denmark1999--2013Cohort267530,41837,531896,448DoPierala \[[@CR76]\]2016UK1992--2009Cohort2033188234152,443Nejdet \[[@CR77]\]2016Sweden2003--2012Cohort115627,08427,912999,804Zhu \[[@CR78]\]2016China2006--2014Cohort9826411105282Vikstrom \[[@CR79]\]2016Sweden1988--2012Case Control60710,41282218,624Ben-Yaakov \[[@CR80]\]2016Israel1988--2012Cohort3784153447195,138Sun \[[@CR81]\]2016China2010--2014Cohort4241154742Valenzuela-Alcaraz \[[@CR26]\]2016Spain2004--2010Cohort64880200Rizzo \[[@CR82]\]2016Italy2007--2014Cohort172496260Guilbaud \[[@CR25]\]2017France2010--2014Cohort4130332369*DOP* Date of publication, *PE* Preeclampsia, *ART* Assisted Reproductive Technology, *NART* Non-Assisted Reproductive Technology

Quantitative data synthesis {#Sec12}
---------------------------

A total of 156,246 ART cases (with 14,560 cases of PE) and 6,558,249 non-ART cases (with 202,064 cases of PE) were included in the analysis. Risk ratios and their 95% CIs were reported using the Mantel--Haenszel method. The relationship of ART and the risk of PE were estimated using the 48 primary included studies. The pooled estimate of RR in this meta-analysis revealed that ART was significantly associated with a higher risk of PE (pooled RR = 1.708, 95% CI = 1.111--2.624, z = 2.44, *p* = 0.015), that is, the PE risk in ART group was 1.687 times greater compared to the non-ART group (Fig. [2](#Fig2){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}).Fig. 2Forest plot showing effect of ART on preeclampsiaTable 3Summary of meta-analysis results and subgroups analysisGroupsStudiesTest of associationHeterogeneityRR (95% CI)*P* valueModelZChi square*P* valueI squareTotal studies481.71 (1.11--2.62)0.015Random2.4426,313.92\< 0.00199.8%Subgroup analysesStudy design Cohort431.73 (1.10--2.72)0.018Random2.3625,159.19\< 0.00199.8% Case control51.46 (0.97--2.20)0.070Random1.8128.38\< 0.00185.9%Time Period 1999--2010181.64 (1.31--2.05)\< 0.001Random4.29117.09\< 0.00185.5% 2010--2017301.74 (0.97--3.09)0.062Random1.8725,671.51\< 0.00199.9%Region Asia111.71 (1.53--1.92)\< 0.001Random9.3817.120.07241.6% Europe261.74 (0.95--3.21)0.075Random1.7825,090.51\< 0.00199.9% America111.78 (1.31--2.41)\< 0.001Random3.7052.30\< 0.00180.9%*RR* Relative Risk, *CI* Confidence Interval

Heterogeneity analysis {#Sec13}
----------------------

Chi-square analysis showed that there was substantial heterogeneity between primary studies (heterogeneity χ^2^ = 26,313.92, *p* \< 0.001, I^2^ = 99.8%, and τ^2^ = 2.17). Therefore, we concluded that the random-effect model was used to pool the studies. To discover the source of heterogeneity, subgroup analysis was carried out on the basis of study design (case control and cohort), study region (United States, Asia, and Europe), and study period (1999--2010 and 2010--2017) (Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}, and Table [3](#Tab3){ref-type="table"}). After subgroup analysis, heterogeneity across studies did not decrease effectively; therefore, all estimations of RR were made by the random-effect model.Fig. 3Forest plot showing effect of ART on preeclampsia based on study designFig. 4Forest plot showing effect of ART on preeclampsia based on study periodFig. 5Forest plot showing effect of ART on preeclampsia based on regions

Risk of publication bias {#Sec14}
------------------------

Both graphical and statistical assessments were performed to check for the presence of publication bias. On the basis of the asymmetrical funnel plot (Fig. [6](#Fig6){ref-type="fig"}) and Begg's test (*p* = 0.001), there was evidence of publication bias in this study. Accordingly, we excluded non-English papers from the meta-analysis and this can lead to bias.Fig. 6Funnel plots of studies examining the association between ART and preeclampsia

Discussion {#Sec15}
==========

This study aimed to evaluate whether several studies agree with the effect of ART on the presence of PE. In this meta-analysis, 6,714,495 cases were recruited (156,246 ART cases and 6,558,249 non-ART cases). To detect the risk of PE regarding the use of ART, the heterogeneity among the studies was assessed, and the appropriate statistical tool was applied. To increase the validity of the results, the risk of publication bias was checked. Analysis of the important subgroups, such as publication date, type of study, and region, was performed.

Similar to the results achieved from our study, most of the studies have introduced the use of ART as a significant risk factor for placental abruption, low and very low birth weight in infants, placenta previa, gestational hypertension, risk of cesarean section, and PE \[[@CR21], [@CR22]\]. However, not all the investigators agree with the adverse effect of ART on pregnancy outcomes \[[@CR23], [@CR24]\]. Most of previous studies have proven the important impact of using ART on PE \[[@CR25]--[@CR28]\]. The positive association between ART and PE is well demonstrated by the included studies. Regarding the magnitude of the effect size, the pooled results from case-control studies were in compliance with those of cohort studies. However, in contrast to the cohort studies, the pooled RR from the case-control studies was not statistically significant. Moreover, the impact of ART on PE did not differ in two distinct periods of time (2010 as the cut-off point). Although consistent results were observed among different regions, the pooled RR from the European studies was not significant. Moreover, the effect size of the Asian and United States studies was higher than that of Europe.

We found that the use of ART was a significant risk factor for PE. The application of ART has increased across many countries around the world as a way to cope with infertility problems. The prevalence of using ART differs among countries. Annually, more than 1.5% of all births in the United States are the result of ART. The prevalence of PE is almost 10% in Africa and 15% in China \[[@CR29]--[@CR32]\]. In addition, the prevalence of PE has an increasing slope. Numerous factors, including the use of ART, hypertension, diabetes, obesity, and early diagnosis problems, are responsible for the ascending trend of PE prevalence \[[@CR30], [@CR33]\]. The adverse outcomes after ART cause damage to body organs, such as the kidney and liver, through PE as well as maternal mortality, perinatal deaths, preterm birth, intrauterine growth restriction, bleeding problems, and fetal growth retardation \[[@CR34], [@CR35]\]. In addition to ART, other factors such as anti-phospholipid syndrome, previous PE, family history of PE, insulin-dependent diabetes, obesity, multiple pregnancies, and nulliparity can affect PE \[[@CR36]\]. The mechanism in which ART affects PE is not well known. However, it has been argued that abnormal placentation can influence PE. In some ART procedures, the blood flow is compromised and is diminished, which is then followed by obstetric complications. Moreover, placental insufficiency is caused by the transfer of the conceptus into the uterine cavity and the impact of the altered hormonal environment in the endometrium where the development of the maternal--fetal interface can be influenced \[[@CR37], [@CR38]\]. It has been argued that ART may have epigenetic effects. The pregnancies from ART are associated with PE through oxidative stress. In addition, ART has several types of reproductive dysfunction with the same strength as miscarriages. Recurrent spontaneous miscarriages, along with infertility treatments, increase the risk of PE in comparison to those without treatment \[[@CR39]\]. Nonetheless, the excess RR in the association between ART and PE can be caused by multiple factors, such as previous fertility complications, lifestyle, smoking habits, long inter-birth intervals, multiple pregnancy, and advanced maternal age \[[@CR39]\]. However, there are many other causal factors associated with infertility itself in which the relationship between PE and ART can be argued.

Thomopoulos et al. assessed the risk of hypertensive disorders in pregnancy following ART using an overview of the studies conducted from 1978 to 2016 \[[@CR40]\]. Their study included papers from PubMed and the Cochrane Collaboration Library databases with a total of 32 papers with PE as an outcome. The present meta-analysis has added primary studies from other databases such as Embase, Scopus, and ISI Web of Knowledge with a total number of 48 papers up to June 2017.

The controversy of using statistical tools to determine the magnitude of heterogeneity in meta-analysis has several potential causes, including sample size and number of the included studies, the period of time, the geographical patterns, the level of development, and the types of studies, etc. In this regard, a non-significant result from a chi-square test must not be taken as evidence of a lack of heterogeneity. Furthermore, the chi-square test is very powerful when many studies are included in a meta-analysis. The other statistical tool to detect heterogeneity, the I^2^ value, depends on the magnitude of the rates \[[@CR41]\]. In our meta-analysis, the result of the chi-square test was confirmed by the I^2^ test. Except for a region of Asia, significant heterogeneities were observed among the pooled and subgroup RRs. The source of heterogeneities may be due to the diversity in the ethnic and cultural conditions and uneven development regions.

However, this study has some limitations. Almost every meta-analysis study deals with uncontrolled confounders. Researchers are not able to control the analysis for the confounders unless the proper information is presented by the original articles. To overcome this problem, "individual patient or participant data (IPD)" is suggested in which requires the detailed information and data-sets from every single original article and it is not applicable in most of the cases regarding that the authors (original articles) might not be interested to present their data and other potential reasons.

This systematic review has several limitations. First, the most important limitation for this study as for other systematic review is the lack of data for subgroup analysis based on type of pregnancy (singleton versus twin pregnancy) or for data analysis controlling for known confounders. Second, our study included only English full-text papers. However, globally published papers might present higher quality research compared with those of local origin.

Conclusion {#Sec16}
==========

The present systematic review and meta-analysis revealed that the use of ART increases the risk of PE considerably. More attention must be paid to Asia and the United States, where the association is stronger and significant.
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